Europe DTC Laboratory Testing Market by Application (Genetic Testing {Ancestry, Carrier Status, Disease Risk [Cancer, Neurological, Cardiac]}, Diabetes, Thyroid, STD, Routine, CBC), Sample Type (Saliva, Urine, Blood) - Forecast to 2030

The Europe DTC Laboratory Testing Market is projected to reach $1.59 billion by 2030, at a CAGR of 10.8% from 2024 to 2030. Direct-to-consumer, DTC tests, or at-home genetic tests, are medical or genetic tests that consumers can order and perform at home without the involvement of a healthcare professional. These tests have become increasingly popular in recent years due to advancements in genetic testing technology and increased consumer interest in understanding their genetic makeup. The sample collected from the consumer is processed at a laboratory, and the results are sent directly to the consumer.

The growth of the Europe direct-to-consumer laboratory testing market is driven by several factors, including the rising incidence of chronic diseases & sexually transmitted diseases, high disposable income, increased consumer awareness, increasing awareness about personal health management, benefits of DTC laboratory testing such as high convenience, affordability, and accessibility, increasing prevalence of chronic and infectious diseases, increasing cost of healthcare, increasing consumer awareness about ancestry/genealogy testing, and the rising elderly population.

Factors such as the growing adoption of telehealth, expansion in emerging economies, and increasing penetration of pharmacogenomic testing in DTC laboratory testing are some opportunities that would help grow the market. Genetic data privacy concerns, misinterpretation of test results, and lack of professional medical counseling could be challenges for the Europe direct-to-consumer laboratory testing market. However, sample integrity and interference issues, regulatory concerns, lack of reimbursement, and the limited test portfolio compared to conventional laboratory testing restrain the market's growth.

Click here to: Get Free Sample Pages of this Report

Ease of Accessibility to DTC Tests and Effective Marketing to Consumers Drives Market Growth

Over the last few years, consumers have been actively participating in decisions affecting their health, enabling people to be informed of their health and lead healthy lifestyles. Clinical laboratory testing is an important part of healthcare. These tests can be ordered online or bought from pharmacies without any prescription, making them easy to access for consumers. The easy accessibility and convenience of ordering the tests online also attract customers.

Companies operating in this market are conducting marketing campaigns and advertisements to interest consumers and inform them about the benefits of DTC tests. This encourages customers to order these tests without needing to consult a physician. By using these DTC tests, consumers can get personalized information about their health, disease risk, and other traits and gain awareness of their genetic predisposition to illnesses. Thus, ease of accessibility to DTC tests and effective marketing to consumers.

Rising Prevalence of Chronic, Infectious, & Sexually Transmitted Diseases

The rising prevalence of chronic & infectious diseases is expected to drive the demand for DTC laboratory testing. Many DTC laboratory testing companies are offering tests for diagnosing infectious diseases and monitoring chronic diseases. In the case of sexually transmitted diseases (STDs), there has been a stigma surrounding it, leading to people not approaching healthcare providers for STD testing. Direct-to-consumer laboratory testing solves this problem by offering discretion and confidentiality to consumers. According to the European Centre for Disease Prevention and Control (ECDC), it is estimated that every year, over 500,000 sexually transmitted infections (STIs) are notified in the U.K. Thus, the advantages of DTC lab testing, such as discretion & confidentiality and the increased prevalence of sexually transmitted diseases, are expected to drive the demand for DTC lab testing.

Key Findings of the Europe DTC Laboratory Testing Market Study:

The Genetic Testing Segment is Expected to Account for the Largest Share of the Market in 2024

Among all the applications, in 2024, the genetic testing segment is expected to account for the largest share of the market. DTC genetic tests are those that are provided directly to consumers without involving a healthcare provider. This testing generally offers a wide range of genetic tests that can be helpful to provide consumers with information about their ancestry, health risks, and traits. This segment is driven by factors such as increasing awareness regarding personal health management, high curiosity about self-ancestry, strong marketing strategies by the companies, rising prevalence of various genetic & chronic diseases, and high demand for personalized testing services.

The Blood Segment is Expected to Account for the Largest Share of the Market in 2024

Among sample types, in 2024, the blood segment is expected to account for the largest share of the market. The blood sample is collected from consumers to test conditions such as diabetes, routine clinical testing, thyroid function, and sexually transmitted disease testing, among others, in order to gain insight into how the organs are functioning. Blood samples are collected using a lancet or a needle that is present in the kit provided to carry out the test. This segment is driven by factors such as a large variety of available tests using blood samples. Increasing prevalence of various chronic diseases and increasing consumer awareness regarding the monitoring of chronic diseases.

Key Players

The key players profiled in the Europe direct-to-consumer laboratory testing market report are LetsGetChecked, Inc. (U.S.), Laboratoire CERBA (France), 23andMe Holding Co. (U.S.), Medichecks.com Ltd. (U.K.), Cerascreen Biotech LLC (U.K.), Living DNA Ltd (U.K.), SelfDiagnostics Deutschland GmbH (Germany), SYNLAB International GmbH (Germany), Natrix S.r.l. (Italy), and Mainz Biomed Germany GmbH (Germany).

The report includes a competitive landscape based on an extensive assessment of the market based on application, sample type,  and geography. The report also provides insights into the geographic presence of major market players and their key growth strategies in the last three to four years.

Scope of the Report:

Europe DTC Laboratory Testing Market, by Application

• Genetic Testing
  • Ancestry/Genealogy
  • Disease Risk Assessment
    • Cancer
    • Cardiovascular Diseases
    • Neurological Diseases
    • Other Diseases
      (Note:Disease risk assessment testing for other diseases includes celiac disease, alpha-1 antitrypsin deficiency, factor XI deficiency, glucose-6-phosphate dehydrogenase deficiency etc.)
  • Carrier Status
  • Other Genetic Tests
    (Note:Other genetic tests primarily include direct-to-consumer genetic testing for pharmacogenomics, skin care DNA tests, and nutrigenomic testing)
• Diabetes Testing
• Routine Clinical Testing
• Thyroid Function Testing
• Sexually Transmitted Disease Testing
• Other Applications
  (Note:Other applications primarily include drug screening, infectious disease testing [Tuberculosis, Chicken pox, Measles, Mumps, Rubella, COVID, UTI], allergy testing, fertility, pregnancy, and nutritional testing.)

Europe DTC Laboratory Testing Market, by Sample Type

• Blood
• Saliva
• Urine
• Other Samples
  (Note:Other samples primarily include stool, nasopharyngeal swab, vaginal swab, buccal swab, and semen.)

Europe DTC Laboratory Testing Market, by Country

• U.K.
• Germany
• France
• Spain
• Italy
• Switzerland
• Netherlands
• Belgium
• Denmark
• Ireland
• Rest of Europe (RoE)

Key questions answered in the report: